Literature DB >> 18987190

Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Maria Traka1, Robert L Wollmann, Sonia R Cerda, Jason Dugas, Ben A Barres, Brian Popko.   

Abstract

Aspartoacylase (ASPA) is an oligodendrocyte-restricted enzyme that catalyzes the hydrolysis of neuronally derived N-acetylaspartate (NAA) to acetate and aspartic acid. ASPA deficiency leads to the fatal childhood autosomal recessive leukodystrophy Canavan disease (CD). Here we demonstrate that the previously described ENU-induced nur7 mouse mutant is caused by a nonsense mutation, Q193X, in the Aspa gene (Aspa(nur7)). Homozygous Aspa(nur7nur7) mice do not express detectable Aspa protein and display an early-onset spongy degeneration of CNS myelin with increased NAA levels similar to that observed in CD patients. In addition, CNS regions rich in neuronal cell bodies also display vacuolization. Interestingly, distinct myelin rich areas, such as the corpus callosum, optic nerve, and spinal cord white matter appear normal in Aspa(nur7/nur7) mice. Reduced cerebroside synthesis has been demonstrated in CD patients and animal models. To determine the potential relevance of this observation in disease pathogenesis, we generated Aspa(nur7/nur7) mice that were heterozygous for a null allele of the gene that encodes the enzyme UDP-galactose:ceramide galactosyltransferase (Cgt), which is responsible for catalyzing the synthesis of the abundant myelin galactolipids. Despite reduced amounts of cerebrosides, the Aspa(nur7/nur7);Cgt(+/-) mice were not more severely affected than the Aspa(nur7) mutants, suggesting that diminished cerebroside synthesis is not a major contributing factor in disease pathogenesis. Furthermore, we found that myelin degeneration leads to significant axonal loss in the cerebellum of older Aspa(nur7) mutants. This finding suggests that axonal pathology caused by CNS myelin defects may underlie the neurological disabilities that CD patients develop at late stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987190      PMCID: PMC2613291          DOI: 10.1523/JNEUROSCI.1490-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

Review 1.  Overview of QTL mapping software and introduction to map manager QT.

Authors:  K F Manly; J M Olson
Journal:  Mamm Genome       Date:  1999-04       Impact factor: 2.957

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  Temporal and regional patterns of axonal damage following traumatic brain injury: a beta-amyloid precursor protein immunocytochemical study in rats.

Authors:  H M Bramlett; S Kraydieh; E J Green; W D Dietrich
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

4.  Myelin galactolipids are essential for proper node of Ranvier formation in the CNS.

Authors:  J L Dupree; T Coetzee; A Blight; K Suzuki; B Popko
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

5.  The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination.

Authors:  N Fujita; A Kemper; J Dupree; H Nakayasu; U Bartsch; M Schachner; N Maeda; K Suzuki; B Popko
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

6.  Effects of galactolipid elimination on oligodendrocyte development and myelination.

Authors:  J Marcus; J L Dupree; B Popko
Journal:  Glia       Date:  2000-06       Impact factor: 7.452

7.  Epileptic seizures induced by N-acetyl-L-aspartate in rats: in vivo and in vitro studies.

Authors:  T Akimitsu; K Kurisu; R Hanaya; K Iida; Y Kiura; K Arita; H Matsubayashi; K Ishihara; K Kitada; T Serikawa; M Sasa
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

8.  Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS.

Authors:  P J Pouwels; J Frahm
Journal:  NMR Biomed       Date:  1997-04       Impact factor: 4.044

9.  In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T.

Authors:  S Blüml
Journal:  J Magn Reson       Date:  1999-02       Impact factor: 2.229

10.  Axo-glial interactions regulate the localization of axonal paranodal proteins.

Authors:  J L Dupree; J A Girault; B Popko
Journal:  J Cell Biol       Date:  1999-12-13       Impact factor: 10.539

View more
  40 in total

1.  Pathophysiology and Treatment of Canavan Disease.

Authors:  David Pleasure; Fuzheng Guo; Olga Chechneva; Peter Bannerman; Jennifer McDonough; Travis Burns; Yan Wang; Vanessa Hull
Journal:  Neurochem Res       Date:  2018-12-08       Impact factor: 3.996

2.  Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Authors:  Jiho Sohn; Peter Bannerman; Fuzheng Guo; Travis Burns; Laird Miers; Christopher Croteau; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

3.  Conditional knockout of TOG results in CNS hypomyelination.

Authors:  Michael J Maggipinto; Joshay Ford; Kristine H Le; Jessica W Tutolo; Miki Furusho; John W Wizeman; Rashmi Bansal; Elisa Barbarese
Journal:  Glia       Date:  2017-01-07       Impact factor: 7.452

Review 4.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

5.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

6.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

7.  ZFP191 is required by oligodendrocytes for CNS myelination.

Authors:  Shen Yi B Howng; Robin L Avila; Ben Emery; Maria Traka; Wensheng Lin; Trent Watkins; Susan Cook; Roderick Bronson; Muriel Davisson; Ben A Barres; Brian Popko
Journal:  Genes Dev       Date:  2010-01-15       Impact factor: 11.361

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

9.  Oligodendrocyte death results in immune-mediated CNS demyelination.

Authors:  Maria Traka; Joseph R Podojil; Derrick P McCarthy; Stephen D Miller; Brian Popko
Journal:  Nat Neurosci       Date:  2015-12-14       Impact factor: 24.884

10.  Discovery of candidate disease genes in ENU-induced mouse mutants by large-scale sequencing, including a splice-site mutation in nucleoredoxin.

Authors:  Melissa K Boles; Bonney M Wilkinson; Laurens G Wilming; Bin Liu; Frank J Probst; Jennifer Harrow; Darren Grafham; Kathryn E Hentges; Lanette P Woodward; Andrea Maxwell; Karen Mitchell; Michael D Risley; Randy Johnson; Karen Hirschi; James R Lupski; Yosuke Funato; Hiroaki Miki; Pablo Marin-Garcia; Lucy Matthews; Alison J Coffey; Anne Parker; Tim J Hubbard; Jane Rogers; Allan Bradley; David J Adams; Monica J Justice
Journal:  PLoS Genet       Date:  2009-12-11       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.